EU Trade Commissioner Announces Reading Rooms For TTIP Text In EU Capitals 05/12/2015 by Intellectual Property Watch 1 Comment European Trade Commissioner Cecilia Malmstroem, speaking to the President of the German Bundestag, Norbert Lammert, announced reading rooms for the consolidated texts of the Transatlantic Trade and Investment Partnership (TTIP) in all capitals of the EU member states.
Law Boosts Awareness, Patents From Research Institutions In South Africa 04/12/2015 by Munyaradzi Makoni for Intellectual Property Watch Leave a Comment CAPE TOWN, South Africa — A law to regulate intellectual property derived from research and development conducted using public funds has boosted the number of patent applications filed and granted by universities and research institutions in the past five years.
IP Summit: Changes In Patent System, Intermediary Liability And The Future Of IP 04/12/2015 by Monika Ermert for Intellectual Property Watch Leave a Comment The stretch run for Europe’s Unitary Patent System (UPS) again took centre stage at the Premier Cercle IP Summit 2015 in Berlin yesterday. Eyes are on Germany for the ratification of the UPS. Cornelia Rudloff-Schäffer, president of the German Patent Office, in the keynote speech assured the 300 hundred participants Germany was preparing for the new system and called out to industry to prepare for the change, saying: “Check your portfolio now.”
Colombia Asked To Declare Excessive Price For Cancer Drug Contrary To Public Interest, Grounds For Compulsory License 03/12/2015 by Intellectual Property Watch 11 Comments Colombia has a decision to make. A full year has passed from the November 24, 2014 request by iFarma, Misión Salud and CIMUN for a declaration of the public interest regarding the cancer drug imatinib (marketed by Novartis as Gleevec/Glivec), the first step on the path toward a compulsory license in Colombia. Thus far, Colombia’s Ministry of Health and Social Protection has failed to act one way or another, leaving patients in limbo and the government at the mercy of a Swiss pharmaceutical giant that reported revenue of over $57.9 Billion USD in 2013, write James Love and Andrew S. Goldman.
Speakers At WIPO Diverge On Patents-Access Relationship; Biologics A Challenge For Generics 03/12/2015 by Catherine Saez, Intellectual Property Watch 3 Comments A seminar on patents and availability of medicines in developing countries yesterday considered whether patents constitute a barrier to access. For the private sector, patents are essential to the innovation system, for others they maintain high prices and should be licensed for easier access. Beyond patents, biologics seem to be taking over the pharmaceutical industry, and the complexity of manufacturing biosimilars might well leave traditional generic manufacturers by the wayside. Separately, a side event at WIPO looked at IP management strategies in private-public partnerships in agriculture and health technologies.
Impact Of The TPP On The Pharma Industry 02/12/2015 by Intellectual Property Watch Leave a Comment The final text of the Trans-Pacific Partnership confirms beyond doubt the apprehensions expressed by civil society, academia and the generic industry about new barriers to access to medicines. The TPP has done away with several flexibilities provided under the TRIPS Agreement and the Doha Declaration on Public Health. Though the text mentions “nothing in this [IPR] Chapter limits a Party’s rights and obligations under Article 31 of the TRIPS Agreement,” the TPP Investment Chapter overrides these flexibilities, says D G Shah.
ARIPO Continues To Build Member State IP Capacities 02/12/2015 by Hillary Muheebwa for Intellectual Property Watch Leave a Comment The African Regional Intellectual Property Organization (ARIPO) recently held two top organ meetings in Lusaka, Zambia, to debate the organisation’s strategic plan for 2016-2020.
US Congressional Study Finds Excessive Profit-Seeking In USD84K Hepatitis Drug Sovaldi 01/12/2015 by Intellectual Property Watch Leave a Comment Two bipartisan United States senators today released the results of an 18-month investigation into the US$84,000 price of the Sovaldi hepatitis C drug, finding the pricing and marketing strategy was aimed at maximizing revenue at the expense of access and affordability. The new report also shows the high impact on US government drug procurement programs and other data.
Ebola Vaccine Team Welcomes New UK R&D Financing, Expects Governments To Join In 01/12/2015 by Tove Iren S. Gerhardsen for Intellectual Property Watch Leave a Comment COPENHAGEN, Denmark — Having led the successful collaborative testing of an Ebola-vaccine in record time, John-Arne Røttingen of the Norwegian Institute of Public Health now wants to expand the idea to a permanent global financing facility for research and development. And he is optimistic.
Medicines Patent Pool Partners with Liverpool University On HIV Nanomedicines 01/12/2015 by Intellectual Property Watch Leave a Comment The Medicines Patent Pool has signed a collaborative agreement with the University of Liverpool to develop HIV nanomedicines.